Anebulo Pharmaceuticals, Inc.
ANEB
$1.05
-$0.02-1.87%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.41% | 32.17% | 38.04% | 36.91% | -19.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.22% | -6.29% | 73.90% | 13.70% | -6.24% |
| Operating Income | -1.22% | 6.29% | -73.90% | -13.70% | 6.24% |
| Income Before Tax | 18.82% | 1.92% | -58.87% | -1.37% | 9.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.82% | 1.92% | -58.87% | -1.37% | 9.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.82% | 1.92% | -58.87% | -1.37% | 9.36% |
| EBIT | -1.22% | 6.29% | -73.90% | -13.70% | 6.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 45.77% | 38.16% | -0.19% | 36.05% | 14.80% |
| Normalized Basic EPS | 45.91% | 38.11% | -0.31% | 36.09% | 14.72% |
| EPS Diluted | 45.77% | 38.16% | -0.19% | 36.05% | 14.80% |
| Normalized Diluted EPS | 45.91% | 38.11% | -0.31% | 36.09% | 14.72% |
| Average Basic Shares Outstanding | 49.86% | 58.43% | 58.43% | 58.43% | 6.30% |
| Average Diluted Shares Outstanding | 49.86% | 58.43% | 58.43% | 58.43% | 6.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |